Skip to main content
. 2014 May 6;16(3):235–246.e1. doi: 10.1016/j.neo.2014.03.005

Figure 6.

Figure 6

Quantification of SMA-positive fibroblasts (A) and F4/80-positive macrophages (B) shows the significantly reduced accumulation of both cell types in sunitinib-treated s.c. HaCaT-rasA-5RT3 tumors compared with the untreated controls. (C) Representative immunostainings for SMA (red), F4/80 (green), and DAPI (blue) of an untreated control and a sunitinib-treated tumor. Bar, 100 μm. Data are presented as means ± SD (**P < .01 and ***P < .001; untreated controls: n = 4; sunitinib-treated tumors: n = 5).